All In Biotech

Drug Trial Radar · NCT00140218

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Last checked: Nov 19, 2026Latest source record: Jan 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Aug 2005

Primary completion

Jan 2007

Study completion Dec 2006

Sponsor

Sponsor type
Individual
Collaborators
University of Pittsburgh
First posted
Sep 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • R(+) pramipexole dihydrochloride monohydrateDrug

    10 mg tid oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ALS-FRSr score taken each month for 3 months during lead-in and for 6 months during treatmentTime frame: -3 -2 -1 0 1 2 3 4 5 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • David Lacomis MD

    Pittsburgh, Pennsylvania

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.